Equities

Medinet Co Ltd

2370:TYO

Medinet Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)40.00
  • Today's Change0.00 / 0.00%
  • Shares traded981.10k
  • 1 Year change-11.11%
  • Beta2.2479
Data delayed at least 20 minutes, as of Nov 22 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year Medinet Co Ltd has grown net income from a loss of -1.44bn to a smaller loss of -1.28bn primarily through revenue growth (661.54m to 768.50m). For while the costs associated with cost of goods, selling, general and administrative and debt all increased as a percentage of sales , the 16.17% growth in revenues contributed enough to still see net income improve.
Gross margin14.66%
Net profit margin-166.17%
Operating margin-181.56%
Return on assets-22.53%
Return on equity-24.95%
Return on investment-23.83%
More ▼

Cash flow in JPYView more

In 2024, Medinet Co Ltd increased its cash reserves by 5.80%, or 254.85m. Cash Flow from Financing totalled 1.46bn or 190.10% of revenues. In addition the company used 1.27bn for operations while cash from investing totalled 65.14m.
Cash flow per share-4.61
Price/Cash flow per share--
Book value per share19.62
Tangible book value per share19.24
More ▼

Balance sheet in JPYView more

Medinet Co Ltd appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio18.64
Quick ratio18.45
Total debt/total equity0.0002
Total debt/total capital0.0002
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.